Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy

Area of Science:

• Endocrinology
• Oncology
• Radiology

Background:

• Prolactinomas are pituitary tumors that secrete prolactin.
• The relationship between prolactin level changes and tumor size reduction is not fully understood.
• Cabergoline is a primary therapy for prolactinomas.

Purpose of the Study:

• To identify a prolactin level threshold predictive of tumor size reduction in macroprolactinoma patients.
• To evaluate the efficacy of cabergoline therapy in reducing macroprolactinoma size.

Main Methods:

• Retrospective cohort study of 123 macroprolactinoma patients.
• Analysis of pituitary hormone assays and sellar MRI scans at baseline and 3 months post-treatment.
• Statistical analysis to determine the association between prolactin levels and tumor shrinkage.

Main Results:

• 88.6% of patients achieved normalized prolactin levels.
• A prolactin level ≤1 ng/mL at 3 months was significantly associated with ≥20% tumor size reduction (OR: 2.8, P=0.017).
• Lower prolactin levels (≤0.7 tertile) correlated with higher rates of significant tumor shrinkage.

Conclusions:

• A post-treatment prolactin level ≤1 ng/mL is a reliable indicator of significant tumor size reduction in macroprolactinoma.
• This biomarker can assist clinicians in managing macroprolactinoma patients treated with cabergoline.